Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|April 10, 2018
Non-Driver NSCLC: Practice Considerations
Non-Driver NSCLC: Practice Considerations
Advertisement
- A 72-year old male presented with dyspnea, weight loss, chronic cough, fatigue, and back pain
- PMH: current non-smoker for the past 10 years with 40-year (1-pack/day) smoking history, COPD, controlled on LABA/LAMA/ICS; hyperlipidemia controlled on atorvastatin
- Chest CT scan showed a 3.5-cm nodule in the upper lobe of the left lung
- MRI of the brain revealed lesions in the left cerebellum and left frontal lobe
- 99mTc bone scan showed increased uptake in the L1 vertebra and eighth rib
- ECOG PS=1
- Pathologic diagnosis of biopsy under bronchoscopy was squamous cell carcinoma
- IHC: PD-L1 expression in 0% of cells
- Patient was started on gemcitabine/cisplatin
- Brain metastases treated with stereotactic radiotherapy
- At 6 months, patient reported worsening fatigue
- Follow up MRI scan showed no evidence of new brain metastases
- CT scan showed new lesions in the right lung and liver
- Patient was started on atezolizumab; ICS medication for COPD was discontinued
- Patient reported decreased appetite, which resolved following implementation of self-management techniques
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5